Parents of deceased Botox patient hit Allergan with lawsuit; FDA approves Zytiga label update;

@FiercePharma: ICYMI yesterday: Merck's Frazier joins top-paid pharma CEOs with a $25M package. Article | Follow @FiercePharma

@EricPFierce: Sounds like Walgreens would like to buy into another drug distributor like AmerisourceBergen. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: The coming generics threat to Pfizer's Viagra brand just got scarier. FiercePharmaMarketing report | Follow @CarlyHFierce

> The parents of a Vermont woman who died last year have sued Botox-maker Allergan ($AGN)--now part of Actavis ($ACT)--saying treatment of her cerebral palsy with the drug helped lead to her death and that the company didn't properly warn of risks. More

> Ireland's pharmaceutical industry has been boosted by a stream of significant new investments in recent years, according to a new report. More

> The FDA has approved a label update for Johnson & Johnson's ($JNJ) Zytiga that includes overall survival results in chemotherapy-naive patients with metastatic castration-resistant prostate cancer. Release

> FDA reviewers have recommended that the agency approve The Medicines Company's ($MDCO) once-rejected blood clot preventer. Report

> Santhera Pharmaceuticals may market a degenerative muscular disease drug on its own in the U.S. to secure a bigger share of revenue and longer patent protection. Report

Medical Device News

@FierceMedDev: EarlySense nabs Mitsui as Japan partner, investor and ups financing to $25M. Article | Follow @FierceMedDev

@VarunSaxena2: ICYMI yesterday: Medtronic joins St. Jude in leadless pacemaker market thanks to CE mark. Report | Follow @VarunSaxena2

@EmilyWFierce: Visual app acts as a "cheat sheet" for docs looking for a quick diagnosis. Wired story | Follow @EmilyWFierce

> Startup raises $4M for sterilization with vaporized hydrogen peroxide. More

> Baxter expanding its manufacturing plant in Arkansas amid preparations to spin off pharma biz. Story

Biotech News

@FierceBiotech: Galapagos' closely-watched rheumatoid arthritis drug filgotinib scores in PhIIb. Report | Follow @FierceBiotech

@JohnCFierce: Meanwhile, back in biotech boomland, Aduro prices at $17 a share. Over the range
$ADRO. Reuters story | Follow @JohnCFierce

> Bayer pours $100M into Bay Area R&D with eyes on hemophilia. Report

> Aduro pulls off a $119M IPO to fund its immuno-oncology pipeline. Story

> Dominant VC NEA gathers $3B, preps for another wave of biotech rounds. Article

Pharma Marketing News

> Eisai rejig means sales-force downsizing at a critical moment for Arena's Belviq. More

> Tech it out: Pfizer, AARP and UnitedHealthcare push innovation. Report

> J&J's Invokana fends off new SGLT2 rivals to hit $278M in Q1. More

> DTC ad viewers really do ask their doctors about new meds, survey finds. Story

> The coming generics threat to Pfizer's Viagra brand just got scarier. Article

Biotech Research News

> Focused on cell signaling, CHOP team preps for human mitochondrial drug study. Report

> UCLA team packs large cargo into cells. Item

> Scripps Parkinson's study points to a key enzyme as a potential drug target. More

> MIT team works on amping up a new approach to cancer immunotherapies. Story

> Chicago project highlights effects of an ancient Chinese cardio remedy. Article

Diagnostics News

> GE and Veracyte team up for disease diagnostic research collaboration. Item

> NIH awards $11M to develop tests for drug-resistant bacteria. Story

> FDA announces LuSys Labs' recall of its unapproved Ebola diagnostic. More

> Roche grabs CAPP Medical to gain ground in cancer Dx. News

> Biocartis joins forces with Microbiome for quick sepsis test. Article

And Finally... Australia is cutting off government welfare for anti-vaxxers. More

Suggested Articles

Last year at ESMO, AZ and Merck showed Lynparza topped its rivals at fending off prostate cancer. Now, Lynparza has helped patients live longer, too.

Merck and Eisai are trying to take their Keytruda-Lenvima combo into additional cancers, and new data provide a glimpse of where it might go next.

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.